Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

AMIT R PALIWAL

Allopathic & Osteopathic Physicians Family Medicine

NPI
1790881159
CMS profile
81770
Location
POMONA, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$474.30

17 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $474.30 17

By paying entity

PY2025 · entire year · sorted by reported total

Page 1 of 1; records 1–17 of 17 matching records. This page contains 17 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

AMIT R PALIWAL

NPI 1790881159 · CMS profile ID 81770

Allopathic & Osteopathic Physicians / Family Medicine

POMONA, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–17 of 17 matching records. This page contains 17 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1790881159?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
AMIT R PALIWAL, NPI 1790881159, CMS profile ID 81770. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–17 of 17 matching records. This page contains 17 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1790881159?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). AMIT R PALIWAL, NPI 1790881159, CMS profile ID 81770. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–17 of 17 matching records. This page contains 17 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1790881159?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
AMIT R PALIWAL, NPI 1790881159, CMS profile ID 81770, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–17 of 17 matching records. This page contains 17 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1790881159?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

17 matching records · $474.30 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 17 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–17 of 17.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Amgen Inc. $13.6112/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227214589 CMS
PFIZER INC. $24.0911/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1230108644 CMS
E.R. Squibb & Sons, L.L.C. $22.7011/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184602938 CMS
AstraZeneca Pharmaceuticals LP $25.3810/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206547391 CMS
Novartis Pharmaceuticals Corporation $32.9610/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200680342 CMS
Exact Sciences Corporation $121.8210/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235362034 CMS
Exact Sciences Corporation $19.1409/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235362030 CMS
Merck Sharp & Dohme LLC $21.8408/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238090635 CMS
Dexcom, Inc. $21.4808/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1250468472 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $23.5007/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223024410 CMS
Novartis Pharmaceuticals Corporation $29.4107/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200680340 CMS
PFIZER INC. $7.2806/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1229220644 CMS
PFIZER INC. $19.8406/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231308696 CMS
Merck Sharp & Dohme LLC $19.8705/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238181267 CMS
Merck Sharp & Dohme LLC $26.6704/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238365197 CMS
Novo Nordisk Inc $26.4502/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1188203222 CMS
Novartis Pharmaceuticals Corporation $18.2601/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200680338 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,553.93 9
PY2020 $223.29 13
PY2021 $428.97 25
PY2022 $224.04 9
PY2023 $595.36 30
PY2024 $2,420.66 49
PY2025 $474.30 17

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $336,771.75 76
PY2024 Principal investigator $1,437,539.26 120
PY2023 Principal investigator $2,154,474.59 360
PY2022 Principal investigator $1,373,629.94 603
PY2021 Principal investigator $148,509.98 11
PY2020 Principal investigator $14,597.00 9
PY2019 Principal investigator $78,504.30 23

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

603 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ModernaTX, Inc. $108,695.56 12/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults 50 Years of Age No dispute reported 06/30/2026 963681217
Principal investigator 1 ModernaTX, Inc. $22,303.70 12/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults 50 Years of Age No dispute reported 06/30/2026 963681221
Principal investigator 1 PFIZER INC. $23,382.72 12/21/2022 Non-covered Recipient Entity
Empire Clinical Research LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949775311
Principal investigator 1 PFIZER INC. $114,440.64 12/17/2022 Non-covered Recipient Entity
Empire Clinical Research LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949775309
Principal investigator 1 ModernaTX, Inc. $13.11 12/16/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567839
Principal investigator 1 ModernaTX, Inc. $669.27 12/16/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567841
Principal investigator 1 ModernaTX, Inc. $13.11 12/16/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567843
Principal investigator 1 ModernaTX, Inc. $669.27 12/16/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567845
Principal investigator 1 ModernaTX, Inc. $909.18 12/16/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567847
Principal investigator 1 ModernaTX, Inc. $669.27 12/16/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567849
Principal investigator 1 ModernaTX, Inc. $909.18 12/16/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567851
Principal investigator 1 ModernaTX, Inc. $669.27 12/16/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567853
Principal investigator 1 ModernaTX, Inc. $909.18 12/16/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567855
Principal investigator 1 ModernaTX, Inc. $669.27 12/16/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567857
Principal investigator 1 ModernaTX, Inc. $669.27 12/16/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567859
Principal investigator 1 ModernaTX, Inc. $669.27 12/16/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567861
Principal investigator 1 ModernaTX, Inc. $3,982.82 12/16/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567863
Principal investigator 1 ModernaTX, Inc. $13.11 12/16/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567865
Principal investigator 1 ModernaTX, Inc. $13.11 12/16/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567867
Principal investigator 1 ModernaTX, Inc. $669.27 12/16/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567869
Principal investigator 1 ModernaTX, Inc. $669.27 12/16/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567871
Principal investigator 1 ModernaTX, Inc. $13.11 12/16/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567873
Principal investigator 1 ModernaTX, Inc. $1,346.40 12/16/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567875
Principal investigator 1 ModernaTX, Inc. $13.11 12/16/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567877
Principal investigator 1 ModernaTX, Inc. $909.18 12/16/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567879
Principal investigator 1 ModernaTX, Inc. $909.18 12/16/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567881
Principal investigator 1 ModernaTX, Inc. $13.11 12/16/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567883
Principal investigator 1 ModernaTX, Inc. $909.18 12/16/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567885
Principal investigator 1 ModernaTX, Inc. $909.18 12/16/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567887
Principal investigator 1 ModernaTX, Inc. $669.27 12/16/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567889
Principal investigator 1 ModernaTX, Inc. $669.27 12/16/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567891
Principal investigator 1 ModernaTX, Inc. $3,982.82 12/16/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567893
Principal investigator 1 ModernaTX, Inc. $669.27 12/16/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567895
Principal investigator 1 ModernaTX, Inc. $1,346.40 12/16/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567897
Principal investigator 1 ModernaTX, Inc. $669.27 12/16/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567899
Principal investigator 1 ModernaTX, Inc. $669.27 12/16/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567901
Principal investigator 1 ModernaTX, Inc. $13.11 12/16/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567903
Principal investigator 1 ModernaTX, Inc. $669.27 12/16/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567905
Principal investigator 1 ModernaTX, Inc. $1,346.40 12/16/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567907
Principal investigator 1 ModernaTX, Inc. $669.27 12/16/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567909
Principal investigator 1 ModernaTX, Inc. $13.11 12/16/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567911
Principal investigator 1 ModernaTX, Inc. $669.27 12/16/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567913
Principal investigator 1 ModernaTX, Inc. $669.27 12/16/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567915
Principal investigator 1 ModernaTX, Inc. $909.18 12/16/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567917
Principal investigator 1 ModernaTX, Inc. $669.27 12/16/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567919
Principal investigator 1 ModernaTX, Inc. $13.11 12/16/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567921
Principal investigator 1 ModernaTX, Inc. $13.11 12/16/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567923
Principal investigator 1 ModernaTX, Inc. $13.11 12/16/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963568001
Principal investigator 1 ModernaTX, Inc. $669.27 12/16/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963568003
Principal investigator 1 ModernaTX, Inc. $669.27 12/16/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963568005
Principal investigator 1 ModernaTX, Inc. $909.18 12/16/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963568007
Principal investigator 1 ModernaTX, Inc. $909.18 12/16/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963568009
Principal investigator 1 ModernaTX, Inc. $13.11 12/16/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963568011
Principal investigator 1 ModernaTX, Inc. $669.27 12/16/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963568013
Principal investigator 1 ModernaTX, Inc. $13.11 12/16/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963568015
Principal investigator 1 ModernaTX, Inc. $669.27 12/16/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963568017
Principal investigator 1 ModernaTX, Inc. $13.11 12/16/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963568019
Principal investigator 1 ModernaTX, Inc. $909.18 12/16/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963568021
Principal investigator 1 ModernaTX, Inc. $669.27 12/16/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963568023
Principal investigator 1 ModernaTX, Inc. $669.27 12/16/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963568025
Principal investigator 1 ModernaTX, Inc. $669.27 12/16/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963568027
Principal investigator 1 ModernaTX, Inc. $13.11 12/16/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963568029
Principal investigator 1 ModernaTX, Inc. $909.18 12/16/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963568031
Principal investigator 1 ModernaTX, Inc. $669.27 12/16/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963568033
Principal investigator 1 ModernaTX, Inc. $909.18 12/16/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963568035
Principal investigator 1 ModernaTX, Inc. $13.11 12/16/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963568037
Principal investigator 1 ModernaTX, Inc. $13.11 12/16/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963568039
Principal investigator 1 ModernaTX, Inc. $13.11 12/16/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963568041
Principal investigator 1 ModernaTX, Inc. $669.27 12/16/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963568043
Principal investigator 1 ModernaTX, Inc. $669.27 12/16/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963568045
Principal investigator 1 ModernaTX, Inc. $3,982.82 12/16/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963568047
Principal investigator 1 ModernaTX, Inc. $13.11 12/16/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963568049
Principal investigator 1 ModernaTX, Inc. $3,982.82 12/16/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963568051
Principal investigator 1 ModernaTX, Inc. $1,346.40 12/16/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963568053
Principal investigator 1 ModernaTX, Inc. $13.11 12/16/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963568055
Principal investigator 1 ModernaTX, Inc. $909.18 12/16/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963568057
Principal investigator 1 ModernaTX, Inc. $3,982.82 12/16/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963568059
Principal investigator 1 ModernaTX, Inc. $669.27 12/16/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963568061
Principal investigator 1 ModernaTX, Inc. $669.27 12/16/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963568063
Principal investigator 1 ModernaTX, Inc. $669.27 12/16/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963568065
Principal investigator 1 ModernaTX, Inc. $13.11 12/16/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963568067
Principal investigator 1 ModernaTX, Inc. $669.27 12/16/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963568069
Principal investigator 1 ModernaTX, Inc. $909.18 12/16/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963568071
Principal investigator 1 ModernaTX, Inc. $669.27 12/16/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963568073
Principal investigator 1 ModernaTX, Inc. $13.11 12/16/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963568075
Principal investigator 1 ModernaTX, Inc. $909.18 12/16/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963568077
Principal investigator 1 ModernaTX, Inc. $1,346.40 12/16/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963568079
Principal investigator 1 ModernaTX, Inc. $669.27 12/16/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963568081
Principal investigator 1 ModernaTX, Inc. $909.18 12/16/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963568083
Principal investigator 1 ModernaTX, Inc. $669.27 12/16/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963568085
Principal investigator 1 ModernaTX, Inc. $909.18 12/16/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963568087
Principal investigator 1 ModernaTX, Inc. $13.11 12/16/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963568089
Principal investigator 1 ModernaTX, Inc. $13.11 12/16/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963568091
Principal investigator 1 ModernaTX, Inc. $13.11 12/16/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963568093
Principal investigator 1 ModernaTX, Inc. $13.11 12/16/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963568095
Principal investigator 1 ModernaTX, Inc. $909.18 12/16/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963568097
Principal investigator 1 ModernaTX, Inc. $669.27 12/16/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963568099
Principal investigator 1 ModernaTX, Inc. $13.11 12/16/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963568103
Principal investigator 1 ModernaTX, Inc. $909.18 12/16/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963568105
Principal investigator 1 ModernaTX, Inc. $909.18 12/16/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963568107
Principal investigator 1 ModernaTX, Inc. $13.11 12/16/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963568109
Principal investigator 1 ModernaTX, Inc. $13.11 12/16/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963568111
Principal investigator 1 ModernaTX, Inc. $13.11 12/16/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963568113
Principal investigator 1 ModernaTX, Inc. $3,982.82 12/16/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963568115
Principal investigator 1 ModernaTX, Inc. $13.11 12/16/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963568117
Principal investigator 1 ModernaTX, Inc. $669.27 12/16/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963568119
Principal investigator 1 ModernaTX, Inc. $669.27 12/16/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963568121
Principal investigator 1 ModernaTX, Inc. $13.11 12/16/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963568123
Principal investigator 1 ModernaTX, Inc. $669.27 12/16/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963568125
Principal investigator 1 PFIZER INC. $65,969.52 12/16/2022 Non-covered Recipient Entity
Empire Clinical Research LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949775605
Principal investigator 1 PFIZER INC. $119,458.32 12/10/2022 Non-covered Recipient Entity
Empire Clinical Research LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949775603
Principal investigator 1 Mylan Technologies Inc. $9,667.78 12/05/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
PHASE 3, MULTICENTER, OPEN-LABEL, SINGLE ARM STUDY OF MR-100A-01 IN WOMEN OF CHILDBEARING POTENTIAL TO EVALUATE CONTRACEPTIVE EFFICACY AND SAFETY No dispute reported 06/30/2026 962739303
Principal investigator 1 PFIZER INC. $26,744.40 12/03/2022 Non-covered Recipient Entity
Empire Clinical Research LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949775779
Principal investigator 1 PFIZER INC. $11,320.00 11/23/2022 Non-covered Recipient Entity
Empire Clinical Research LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949781267
Principal investigator 1 ModernaTX, Inc. $909.18 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963566927
Principal investigator 1 ModernaTX, Inc. $909.18 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963566929
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963566931
Principal investigator 1 ModernaTX, Inc. $3,982.82 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963566933
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963566935
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963566937
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963566939
Principal investigator 1 ModernaTX, Inc. $3,982.82 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963566941
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963566943
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963566945
Principal investigator 1 ModernaTX, Inc. $909.18 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963566947
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963566953
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963566955
Principal investigator 1 ModernaTX, Inc. $3,982.82 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963566957
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963566963
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963566965
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963566967
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963566969
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963566971
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963566977
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963566979
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963566981
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963566983
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963566985
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963566989
Principal investigator 1 ModernaTX, Inc. $909.18 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963566991
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963566993
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963566995
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963566997
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963566999
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567001
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567003
Principal investigator 1 ModernaTX, Inc. $3,982.82 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567005
Principal investigator 1 ModernaTX, Inc. $3,982.82 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567015
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567017
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567019
Principal investigator 1 ModernaTX, Inc. $3,982.82 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567021
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567023
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567027
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567029
Principal investigator 1 ModernaTX, Inc. $909.18 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567031
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567033
Principal investigator 1 ModernaTX, Inc. $3,982.82 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567035
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567037
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567039
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567041
Principal investigator 1 ModernaTX, Inc. $3,982.82 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567043
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567049
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567051
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567053
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567055
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567057
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567059
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567061
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567063
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567065
Principal investigator 1 ModernaTX, Inc. $3,982.82 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567067
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567069
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567075
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567077
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567081
Principal investigator 1 ModernaTX, Inc. $3,982.82 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567083
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567085
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567087
Principal investigator 1 ModernaTX, Inc. $909.18 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567089
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567091
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567093
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567095
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567097
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567099
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567105
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567107
Principal investigator 1 ModernaTX, Inc. $909.18 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567109
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567111
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567113
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567119
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567121
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567123
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567125
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567127
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567129
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567131
Principal investigator 1 ModernaTX, Inc. $3,982.82 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567133
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567135
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567141
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567143
Principal investigator 1 ModernaTX, Inc. $909.18 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567145
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567147
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567149
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567155
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567157
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567159
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567161
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567167
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567169
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567179
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567181
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567183
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567185
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567187
Principal investigator 1 ModernaTX, Inc. $3,982.82 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567189
Principal investigator 1 ModernaTX, Inc. $909.18 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567191
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567193
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567195
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567197
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567199
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567201
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567203
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567209
Principal investigator 1 ModernaTX, Inc. $909.18 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567211
Principal investigator 1 ModernaTX, Inc. $909.18 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567213
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567223
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567225
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567227
Principal investigator 1 ModernaTX, Inc. $3,982.82 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567229
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567235
Principal investigator 1 ModernaTX, Inc. $3,982.82 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567237
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567239
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567241
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567243
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567245
Principal investigator 1 ModernaTX, Inc. $3,982.82 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567247
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567253
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567255
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567257
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567259
Principal investigator 1 ModernaTX, Inc. $3,982.82 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567261
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567263
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567275
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567277
Principal investigator 1 ModernaTX, Inc. $909.18 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567279
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567281
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567283
Principal investigator 1 ModernaTX, Inc. $909.18 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567287
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567289
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567291
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567297
Principal investigator 1 ModernaTX, Inc. $909.18 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567299
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567301
Principal investigator 1 ModernaTX, Inc. $3,982.82 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567303
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567305
Principal investigator 1 ModernaTX, Inc. $3,982.82 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567307
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567317
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567327
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567329
Principal investigator 1 ModernaTX, Inc. $3,982.82 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567333
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567335
Principal investigator 1 ModernaTX, Inc. $909.18 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567343
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567345
Principal investigator 1 ModernaTX, Inc. $3,982.82 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567347
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567349
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567351
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567353
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567355
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567357
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567359
Principal investigator 1 ModernaTX, Inc. $3,982.82 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567361
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567363
Principal investigator 1 ModernaTX, Inc. $3,982.82 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567371
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567373
Principal investigator 1 ModernaTX, Inc. $3,982.82 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567375
Principal investigator 1 ModernaTX, Inc. $3,982.82 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567377
Principal investigator 1 ModernaTX, Inc. $909.18 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567379
Principal investigator 1 ModernaTX, Inc. $909.18 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567381
Principal investigator 1 ModernaTX, Inc. $3,982.82 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567389
Principal investigator 1 ModernaTX, Inc. $3,982.82 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567391
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567393
Principal investigator 1 ModernaTX, Inc. $909.18 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567395
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567397
Principal investigator 1 ModernaTX, Inc. $3,982.82 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567399
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567401
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567415
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567417
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567419
Principal investigator 1 ModernaTX, Inc. $909.18 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567421
Principal investigator 1 ModernaTX, Inc. $3,982.82 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567423
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567425
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567431
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567433
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567435
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567437
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567447
Principal investigator 1 ModernaTX, Inc. $3,982.82 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567449
Principal investigator 1 ModernaTX, Inc. $3,982.82 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567451
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567453
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567459
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567461
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567463
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567465
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567467
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567469
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567473
Principal investigator 1 ModernaTX, Inc. $909.18 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567475
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567477
Principal investigator 1 ModernaTX, Inc. $3,982.82 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567479
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567481
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567487
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567489
Principal investigator 1 ModernaTX, Inc. $909.18 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567491
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567493
Principal investigator 1 ModernaTX, Inc. $909.18 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567495
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567497
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567501
Principal investigator 1 ModernaTX, Inc. $909.18 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567503
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567507
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567509
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567511
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567513
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567515
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567521
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567523
Principal investigator 1 ModernaTX, Inc. $909.18 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567525
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567527
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567529
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567531
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567533
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567535
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567539
Principal investigator 1 ModernaTX, Inc. $909.18 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567541
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567543
Principal investigator 1 ModernaTX, Inc. $909.18 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567545
Principal investigator 1 ModernaTX, Inc. $909.18 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567553
Principal investigator 1 ModernaTX, Inc. $3,982.82 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567555
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567557
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567559
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567567
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567569
Principal investigator 1 ModernaTX, Inc. $3,982.82 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567571
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567573
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567575
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567577
Principal investigator 1 ModernaTX, Inc. $3,982.82 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567579
Principal investigator 1 ModernaTX, Inc. $3,982.82 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567581
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567583
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567585
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567587
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567589
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567593
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567595
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567597
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567599
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567601
Principal investigator 1 ModernaTX, Inc. $909.18 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567603
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567605
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567607
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567609
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567611
Principal investigator 1 ModernaTX, Inc. $3,982.82 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567627
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567629
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567631
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567633
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567635
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567637
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567639
Principal investigator 1 ModernaTX, Inc. $909.18 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567641
Principal investigator 1 ModernaTX, Inc. $909.18 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567647
Principal investigator 1 ModernaTX, Inc. $3,982.82 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567649
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567651
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567653
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567655
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567657
Principal investigator 1 ModernaTX, Inc. $909.18 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567659
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567663
Principal investigator 1 ModernaTX, Inc. $3,982.82 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567671
Principal investigator 1 ModernaTX, Inc. $909.18 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567673
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567675
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567677
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567679
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567681
Principal investigator 1 ModernaTX, Inc. $909.18 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567687
Principal investigator 1 ModernaTX, Inc. $909.18 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567689
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567691
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567693
Principal investigator 1 ModernaTX, Inc. $3,982.82 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567695
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567697
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567701
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567703
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567705
Principal investigator 1 ModernaTX, Inc. $909.18 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567707
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567709
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567711
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567713
Principal investigator 1 ModernaTX, Inc. $3,982.82 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567715
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567719
Principal investigator 1 ModernaTX, Inc. $3,982.82 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567721
Principal investigator 1 ModernaTX, Inc. $3,982.82 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567723
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567725
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567727
Principal investigator 1 ModernaTX, Inc. $3,982.82 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567729
Principal investigator 1 ModernaTX, Inc. $3,982.82 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567731
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567733
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567741
Principal investigator 1 ModernaTX, Inc. $3,982.82 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567749
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567751
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567753
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567759
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567761
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567763
Principal investigator 1 ModernaTX, Inc. $909.18 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567765
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567767
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567769
Principal investigator 1 ModernaTX, Inc. $909.18 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567771
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567775
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567777
Principal investigator 1 ModernaTX, Inc. $3,982.82 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567779
Principal investigator 1 ModernaTX, Inc. $3,982.82 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567781
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567783
Principal investigator 1 ModernaTX, Inc. $909.18 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567785
Principal investigator 1 ModernaTX, Inc. $3,982.82 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567791
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567793
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567795
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567797
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567799
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567801
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567803
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567811
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567813
Principal investigator 1 ModernaTX, Inc. $3,982.82 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567815
Principal investigator 1 ModernaTX, Inc. $909.18 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567817
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567819
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567821
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567823
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567829
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567831
Principal investigator 1 ModernaTX, Inc. $13.11 11/21/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567833
Principal investigator 1 PFIZER INC. $149.04 11/21/2022 Non-covered Recipient Entity
Empire Clinical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949760003
Principal investigator 1 ModernaTX, Inc. $199,282.00 11/18/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults 50 Years of Age No dispute reported 06/30/2026 963681145
Principal investigator 1 ModernaTX, Inc. $1,973.64 11/18/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults 50 Years of Age No dispute reported 06/30/2026 963681147
Principal investigator 1 PFIZER INC. $93.15 11/16/2022 Non-covered Recipient Entity
Empire Clinical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949759241
Principal investigator 1 PFIZER INC. $18.63 11/16/2022 Non-covered Recipient Entity
Empire Clinical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949759243
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963566923
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963566925
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963566949
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963566951
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963566959
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963566961
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963566973
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963566975
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963566987
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567007
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567009
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567011
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567013
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567025
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567045
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567047
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567071
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567073
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567079
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567101
Principal investigator 1 ModernaTX, Inc. $3,982.82 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567103
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567115
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567117
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567137
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567139
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567151
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567153
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567163
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567165
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567171
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567173
Principal investigator 1 ModernaTX, Inc. $3,982.82 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567175
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567177
Principal investigator 1 ModernaTX, Inc. $3,982.82 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567205
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567207
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567215
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567217
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567219
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567221
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567231
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567233
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567249
Principal investigator 1 ModernaTX, Inc. $3,982.82 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567251
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567265
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567267
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567269
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567271
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567273
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567285
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567293
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567295
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567309
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567311
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567313
Principal investigator 1 ModernaTX, Inc. $3,982.82 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567315
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567319
Principal investigator 1 ModernaTX, Inc. $3,982.82 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567321
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567323
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567325
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567337
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567339
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567341
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567365
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567367
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567369
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567383
Principal investigator 1 ModernaTX, Inc. $3,982.82 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567385
Principal investigator 1 ModernaTX, Inc. $3,982.82 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567387
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567403
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567405
Principal investigator 1 ModernaTX, Inc. $3,982.82 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567407
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567409
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567411
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567413
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567427
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567429
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567439
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567441
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567443
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567445
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567455
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567457
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567471
Principal investigator 1 ModernaTX, Inc. $3,982.82 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567483
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567485
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567499
Principal investigator 1 ModernaTX, Inc. $3,982.82 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567505
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567517
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567519
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567537
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567547
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567549
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567551
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567561
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567563
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567565
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567591
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567613
Principal investigator 1 ModernaTX, Inc. $3,982.82 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567615
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567617
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567619
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567621
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567623
Principal investigator 1 ModernaTX, Inc. $3,982.82 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567625
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567643
Principal investigator 1 ModernaTX, Inc. $3,982.82 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567645
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567661
Principal investigator 1 ModernaTX, Inc. $3,982.82 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567665
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567667
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567669
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567683
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567685
Principal investigator 1 ModernaTX, Inc. $3,982.82 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567699
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567717
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567735
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567737
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567739
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567743
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567745
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567747
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567755
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567757
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567773
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567787
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567789
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567805
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567807
Principal investigator 1 ModernaTX, Inc. $3,982.82 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567809
Principal investigator 1 ModernaTX, Inc. $3,982.82 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567825
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567827
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567835
Principal investigator 1 ModernaTX, Inc. $13.11 11/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963567837
Principal investigator 1 ModernaTX, Inc. $24,943.73 11/02/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults 50 Years of Age No dispute reported 06/30/2026 963681143
Principal investigator 1 ModernaTX, Inc. $1,696.15 10/26/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults 50 Years of Age No dispute reported 06/30/2026 963681141
Principal investigator 1 PFIZER INC. $55.89 10/19/2022 Non-covered Recipient Entity
Empire Clinical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949759179
Principal investigator 1 ModernaTX, Inc. $62,992.18 10/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults 50 Years of Age No dispute reported 06/30/2026 963681139
Principal investigator 1 ModernaTX, Inc. $42.00 10/06/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963294815
Principal investigator 1 ModernaTX, Inc. $46,921.85 10/05/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults 50 Years of Age No dispute reported 06/30/2026 963681137
Principal investigator 1 PFIZER INC. $555.28 09/30/2022 Non-covered Recipient Entity
Empire Clinical Research LLC
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 949792545
Principal investigator 1 PFIZER INC. $22,211.20 09/24/2022 Non-covered Recipient Entity
Empire Clinical Research LLC
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 949792645
Principal investigator 1 ModernaTX, Inc. $498.00 09/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963294751
Principal investigator 1 Organon LLC $2,586.00 09/14/2022 Non-covered Recipient Entity
Empire Clinical Research, LLC
OG-8175A-023 No dispute reported 06/30/2026 938723941
Principal investigator 1 Organon LLC $10,000.00 09/14/2022 Non-covered Recipient Entity
Empire Clinical Research, LLC
OG-8175A-023 No dispute reported 06/30/2026 938723943
Principal investigator 1 ModernaTX, Inc. $498.00 09/12/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963294757
Principal investigator 1 PFIZER INC. $5,879.31 08/16/2022 Non-covered Recipient Entity
Empire Clinical Research LLC
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 949804095
Principal investigator 1 PFIZER INC. $2,702.56 07/29/2022 Non-covered Recipient Entity
Empire Clinical Research LLC
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 949807873
Principal investigator 1 PFIZER INC. $2,026.92 06/29/2022 Non-covered Recipient Entity
Empire Clinical Research LLC
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 949811977
Principal investigator 1 PFIZER INC. $5,742.94 06/15/2022 Non-covered Recipient Entity
Empire Clinical Research LLC
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 949811975
Principal investigator 1 PFIZER INC. $1,689.10 05/27/2022 Non-covered Recipient Entity
Empire Clinical Research LLC
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 949748379
Principal investigator 1 PFIZER INC. $337.82 05/14/2022 Non-covered Recipient Entity
Empire Clinical Research LLC
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 949749787
Principal investigator 1 PFIZER INC. $675.64 04/29/2022 Non-covered Recipient Entity
Empire Clinical Research LLC
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 949819557
Principal investigator 1 PFIZER INC. $893.76 04/14/2022 Non-covered Recipient Entity
Empire Clinical Research LLC
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 949819265
Principal investigator 1 PFIZER INC. $2,681.28 04/01/2022 Non-covered Recipient Entity
Empire Clinical Research LLC
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 949819263
Principal investigator 1 PFIZER INC. $5,693.09 03/16/2022 Non-covered Recipient Entity
Empire Clinical Research LLC
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 949826219
Principal investigator 1 PFIZER INC. $19,329.63 02/25/2022 Non-covered Recipient Entity
Empire Clinical Research LLC
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 949830009
Principal investigator 1 PFIZER INC. $46,254.81 02/04/2022 Non-covered Recipient Entity
Empire Clinical Research LLC
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 949830007
Principal investigator 1 GlaxoSmithKline, LLC. $1,627.65 01/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO DEMONSTRA No dispute reported 06/30/2026 943939755
Principal investigator 1 GlaxoSmithKline, LLC. $7,053.17 01/14/2022 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO DEMONSTRA No dispute reported 06/30/2026 943939757
Principal investigator 1 PFIZER INC. $10,709.18 01/08/2022 Non-covered Recipient Entity
Empire Clinical Research LLC
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 949831553